Deferasirox Fe3+ Chelate: Oral Iron Chelator for Iron Overload Research

Executive Summary: Deferasirox Fe3+ chelate is a tridentate oral iron chelator designed to bind and remove excess ferric iron (Fe3+) in research models of iron overload (APExBIO). It is highly relevant for beta-thalassemia and chronic anemia studies, where chronic transfusion therapy leads to iron accumulation and organ toxicity (Galanello et al., 2012). The compound demonstrates strong solubility in DMSO (≥53.5 mg/mL) and ethanol (≥12.68 mg/mL), but is insoluble in water. Optimized for research use, it is supplied at 98% purity and should be stored at -20°C for stability. Deferasirox Fe3+ chelate underpins modern iron chelation workflows and provides a benchmark for evaluating iron homeostasis interventions.

Biological Rationale

Iron overload is a direct consequence of repeated blood transfusions, common in chronic anemias such as beta-thalassemia, sickle cell disease, and myelodysplastic syndromes (Galanello et al., 2012). Excess iron accumulates because the human body lacks a regulated excretion pathway for iron. Chronic iron overload leads to organ damage, especially in the heart and liver, and is associated with increased morbidity and mortality. More than 50% of patient deaths in thalassemia major are linked to cardiac complications caused by iron toxicity (Galanello et al., 2012). Untreated iron overload in transfusion-dependent patients leads to reduced life expectancy and impacts quality of life.

Mechanism of Action of Deferasirox Fe3+ chelate

Deferasirox Fe3+ chelate (Exjade Fe3+ chelate) is a tridentate ligand that selectively binds ferric iron (Fe3+) ions. Each molecule coordinates with Fe3+ to form a stable, water-insoluble complex, which can then be excreted from the body (Galanello et al., 2012). This chelation prevents free iron from catalyzing the formation of reactive oxygen species (ROS), thereby reducing oxidative stress and organ damage. Chemically, deferasirox Fe3+ chelate is identified as 4-[3,5-bis(2-oxidophenyl)-1,2,4-triazol-1-yl]benzoate;iron(3+), with a molecular weight of 426.18 and CAS number 554435-83-5 (APExBIO). The compound’s tridentate structure confers high specificity for Fe3+, minimizing interactions with other biologically important metal ions. For more on lysosomal iron handling, see this article; this current review expands on mechanistic nuances of iron binding and workflow parameters.

Evidence & Benchmarks

• Deferasirox (Exjade) is clinically validated for reducing iron overload in transfusion-dependent beta-thalassemia and other anemias (Galanello et al., 2012).
• It demonstrates oral bioavailability and a manageable safety profile in both pediatric and adult populations (Galanello et al., 2012).
• In research settings, Deferasirox Fe3+ chelate exhibits solubility ≥53.5 mg/mL in DMSO and ≥12.68 mg/mL in ethanol at room temperature, but is insoluble in water (APExBIO).
• Storage at -20°C is recommended to maintain compound stability; prolonged solution storage is discouraged (APExBIO).
• Compared to deferoxamine, Deferasirox offers improved workflow integration due to its oral administration and better patient compliance in clinical scenarios (Galanello et al., 2012).

Applications, Limits & Misconceptions

Deferasirox Fe3+ chelate is widely adopted in iron overload treatment research, especially for modeling chronic transfusion-induced iron accumulation in beta-thalassemia and chronic anemia (related review). This article extends previous work by detailing optimal solvent use and storage parameters for reproducible workflows. The compound is also used to probe iron metabolism, ferritinophagy, and oxidative stress pathways in cell culture and animal models (see further mechanistic analysis).

Common Pitfalls or Misconceptions

• Deferasirox Fe3+ chelate is not soluble in water; attempting aqueous dissolution reduces yield and reproducibility.
• The compound is intended for research use only and is not approved for direct clinical or diagnostic application.
• Solutions are unstable upon prolonged storage; fresh preparation is critical for consistent results.
• Chelation selectivity: Deferasirox primarily binds Fe3+ and should not be used for chelation of divalent (Fe2+) or other metal ions.
• Improper storage (above -20°C) may reduce compound purity and chelation efficacy.

Workflow Integration & Parameters

Deferasirox Fe3+ chelate is supplied by APExBIO as SKU A3355 at ≥98% purity and is formulated for research applications. For in vitro studies, dissolve in DMSO or ethanol to the desired concentration; avoid water as a solvent (product details). Recommended working concentrations depend on model system and research objective, typically ranging from low micromolar to millimolar. Store powder at -20°C with desiccation. Use freshly prepared solutions and avoid repeated freeze-thaw cycles. The product is not intended for human or animal therapeutic use. For integration into iron metabolism or cell signaling workflows involving NF-κB or ferritinophagy, see this comparative analysis, which this article updates with technical solvent and purity benchmarks.

Conclusion & Outlook

Deferasirox Fe3+ chelate is a cornerstone tool for iron overload treatment research and iron metabolism studies. Its high purity, selective Fe3+ binding, and optimized solubility profile enable robust integration into preclinical models of beta-thalassemia, chronic anemia, and iron-induced toxicity. As research advances, APExBIO’s Deferasirox Fe3+ chelate (A3355) will continue to support investigations into iron homeostasis, oxidative stress, and metabolic adaptation. Future studies may expand its utility in novel disease models and mechanistic workflows, but rigorous attention to solvent choice, storage, and compound specificity remains essential for reproducible results.